JP2014034577A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014034577A5 JP2014034577A5 JP2013226693A JP2013226693A JP2014034577A5 JP 2014034577 A5 JP2014034577 A5 JP 2014034577A5 JP 2013226693 A JP2013226693 A JP 2013226693A JP 2013226693 A JP2013226693 A JP 2013226693A JP 2014034577 A5 JP2014034577 A5 JP 2014034577A5
- Authority
- JP
- Japan
- Prior art keywords
- csf
- mgd
- shows
- cells
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000000694 effects Effects 0.000 claims description 18
- 108090001123 antibodies Proteins 0.000 claims description 14
- 102000004965 antibodies Human genes 0.000 claims description 14
- 230000035755 proliferation Effects 0.000 claims description 7
- 230000004936 stimulating Effects 0.000 claims description 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 230000028993 immune response Effects 0.000 claims 3
- 230000000051 modifying Effects 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 3
- 206010003816 Autoimmune disease Diseases 0.000 claims 2
- 201000009596 autoimmune hypersensitivity disease Diseases 0.000 claims 2
- 210000002865 immune cell Anatomy 0.000 claims 2
- 208000007788 Acute Liver Failure Diseases 0.000 claims 1
- 206010000804 Acute hepatic failure Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010021972 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010039073 Rheumatoid arthritis Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 200000000018 inflammatory disease Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 108010045030 monoclonal antibodies Proteins 0.000 claims 1
- 102000005614 monoclonal antibodies Human genes 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 108091008117 polyclonal antibodies Proteins 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 201000004681 psoriasis Diseases 0.000 claims 1
- 230000001629 suppression Effects 0.000 claims 1
- 210000004027 cells Anatomy 0.000 description 40
- 230000004069 differentiation Effects 0.000 description 22
- 230000015572 biosynthetic process Effects 0.000 description 12
- 238000005755 formation reaction Methods 0.000 description 12
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 11
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 11
- 210000001616 Monocytes Anatomy 0.000 description 11
- 238000003260 fluorescence intensity Methods 0.000 description 10
- 210000000822 Killer Cells, Natural Anatomy 0.000 description 9
- 230000004663 cell proliferation Effects 0.000 description 9
- 239000002609 media Substances 0.000 description 9
- 102100003268 CD14 Human genes 0.000 description 8
- 101700027514 CD14 Proteins 0.000 description 8
- 210000004443 Dendritic Cells Anatomy 0.000 description 8
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 8
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 8
- 239000000427 antigen Substances 0.000 description 8
- 102000038129 antigens Human genes 0.000 description 8
- 108091007172 antigens Proteins 0.000 description 8
- 108060001249 CD24 Proteins 0.000 description 7
- 102100000197 CD24 Human genes 0.000 description 7
- 210000003714 Granulocytes Anatomy 0.000 description 7
- 210000003958 Hematopoietic Stem Cells Anatomy 0.000 description 7
- 231100000673 dose–response relationship Toxicity 0.000 description 7
- 210000001185 Bone Marrow Anatomy 0.000 description 6
- 230000001143 conditioned Effects 0.000 description 6
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 6
- 210000002791 CFU-M Anatomy 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 239000003636 conditioned culture media Substances 0.000 description 5
- 102100015541 FCGR3A Human genes 0.000 description 4
- 101710044656 FCGR3A Proteins 0.000 description 4
- 101710044657 FCGR3B Proteins 0.000 description 4
- 102100019327 FUT4 Human genes 0.000 description 4
- 101700004786 FUT4 Proteins 0.000 description 4
- 210000004693 NK cell Anatomy 0.000 description 4
- 239000005089 Luciferase Substances 0.000 description 3
- 108060001084 Luciferase family Proteins 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 230000003834 intracellular Effects 0.000 description 3
- 210000004962 mammalian cells Anatomy 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- 230000004083 survival Effects 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 229940098773 Bovine Serum Albumin Drugs 0.000 description 2
- 108091003117 Bovine Serum Albumin Proteins 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 210000000066 Myeloid Cells Anatomy 0.000 description 2
- 229920001850 Nucleic acid sequence Polymers 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 210000002966 Serum Anatomy 0.000 description 2
- 102200022459 TNFRSF13C C35S Human genes 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229960005188 collagen Drugs 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 230000001332 colony forming Effects 0.000 description 2
- 230000001419 dependent Effects 0.000 description 2
- 239000010432 diamond Substances 0.000 description 2
- 150000007523 nucleic acids Chemical group 0.000 description 2
- 230000002062 proliferating Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- 108060001251 CD34 Proteins 0.000 description 1
- 102100016492 CD34 Human genes 0.000 description 1
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 description 1
- 229920000665 Exon Polymers 0.000 description 1
- 229960002897 Heparin Drugs 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N Heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 101700086956 IFNG Proteins 0.000 description 1
- 102100016020 IFNG Human genes 0.000 description 1
- 102100008995 IL34 Human genes 0.000 description 1
- 108020005242 IL34 Proteins 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 239000012614 Q-Sepharose Substances 0.000 description 1
- 230000037165 Serum Concentration Effects 0.000 description 1
- 230000001464 adherent Effects 0.000 description 1
- 238000004115 adherent culture Methods 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 230000001580 bacterial Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 1
- 230000001809 detectable Effects 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 231100000171 higher toxicity Toxicity 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000002093 peripheral Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 230000002195 synergetic Effects 0.000 description 1
- 230000001131 transforming Effects 0.000 description 1
- 230000001052 transient Effects 0.000 description 1
Description
Claims (5)
- 被験体において免疫応答を調節するための組成物であって、
(a)配列番号7、9または10のいずれかのアミノ酸配列を含み、かつ免疫細胞の増殖を刺激する活性を有するポリペプチド、および
(b)配列番号7、9または10のいずれかのアミノ酸配列に少なくとも95%同一なアミノ酸配列を含み、かつ免疫細胞の増殖を刺激する活性を有する、ポリペプチド
から選択されるポリペプチドに特異的な抗体
を含み、該免疫応答の調節が、炎症の抑制および/または自己免疫疾患の抑制である、組成物。 - 前記抗体が、モノクローナル抗体、ポリクローナル抗体、単鎖抗体および抗体の活性フラグメントから選択される、請求項1に記載の組成物。
- 前記免疫応答の調節が、関節リウマチ、変形性関節炎、乾癬、炎症性腸疾患、多発性硬化症、および劇症肝不全より選択される疾患の処置または予防である、請求項1に記載の組成物。
- 炎症性疾患の患者に投与するための、請求項1または2に記載の組成物。
- 自己免疫疾患の患者に投与するための、請求項1または2に記載の組成物。
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US59056504P | 2004-07-22 | 2004-07-22 | |
US60/590,565 | 2004-07-22 | ||
US64760405P | 2005-01-27 | 2005-01-27 | |
US60/647,604 | 2005-01-27 | ||
US66493205P | 2005-03-24 | 2005-03-24 | |
US60/664,932 | 2005-03-24 | ||
US69901905P | 2005-07-14 | 2005-07-14 | |
US60/699,019 | 2005-07-14 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007522769A Division JP5435865B2 (ja) | 2004-07-22 | 2005-07-21 | 疾患処置におけるmgd−csfのための組成物およびその使用方法 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015029580A Division JP2015133970A (ja) | 2004-07-22 | 2015-02-18 | 疾患処置におけるmgd−csfのための組成物およびその使用方法 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2014034577A JP2014034577A (ja) | 2014-02-24 |
JP2014034577A5 true JP2014034577A5 (ja) | 2015-04-09 |
JP5815638B2 JP5815638B2 (ja) | 2015-11-17 |
Family
ID=35448388
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007522769A Expired - Fee Related JP5435865B2 (ja) | 2004-07-22 | 2005-07-21 | 疾患処置におけるmgd−csfのための組成物およびその使用方法 |
JP2013226693A Expired - Fee Related JP5815638B2 (ja) | 2004-07-22 | 2013-10-31 | 疾患処置におけるmgd−csfのための組成物およびその使用方法 |
JP2015029580A Pending JP2015133970A (ja) | 2004-07-22 | 2015-02-18 | 疾患処置におけるmgd−csfのための組成物およびその使用方法 |
JP2016103092A Pending JP2016146850A (ja) | 2004-07-22 | 2016-05-24 | 疾患処置におけるmgd−csfのための組成物およびその使用方法 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007522769A Expired - Fee Related JP5435865B2 (ja) | 2004-07-22 | 2005-07-21 | 疾患処置におけるmgd−csfのための組成物およびその使用方法 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015029580A Pending JP2015133970A (ja) | 2004-07-22 | 2015-02-18 | 疾患処置におけるmgd−csfのための組成物およびその使用方法 |
JP2016103092A Pending JP2016146850A (ja) | 2004-07-22 | 2016-05-24 | 疾患処置におけるmgd−csfのための組成物およびその使用方法 |
Country Status (8)
Country | Link |
---|---|
US (4) | US20070264277A1 (ja) |
EP (3) | EP2479277B1 (ja) |
JP (4) | JP5435865B2 (ja) |
AT (1) | ATE540973T1 (ja) |
AU (1) | AU2005267062C1 (ja) |
CA (1) | CA2574654C (ja) |
HK (2) | HK1100223A1 (ja) |
WO (1) | WO2006012451A2 (ja) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7294704B2 (en) | 2003-08-15 | 2007-11-13 | Diadexus, Inc. | Pro108 antibody compositions and methods of use and use of Pro108 to assess cancer risk |
ATE454455T1 (de) * | 2005-01-27 | 2010-01-15 | Five Prime Therapeutics Inc | Leitsequenzen zur anleitung von polypeptidsekretion und verfahren zur herstellung |
WO2008073660A1 (en) * | 2006-11-09 | 2008-06-19 | University Of Washington | Molecules and methods for treatment and detection of cancer |
CA2719582A1 (en) * | 2008-03-25 | 2009-10-01 | Amarantus Therapeutics, Inc. | Methods and compositions for treating parkinson's disease with manf |
WO2009137631A2 (en) * | 2008-05-07 | 2009-11-12 | Wintherix Llc | Methods for identifying compounds that affect expression of cancer-related protein isoforms |
WO2010062401A2 (en) | 2008-11-26 | 2010-06-03 | Five Prime Therapeutics, Inc. | Treatment of osteolytic disorders and cancer using csf1r extracellular domain fusion molecules |
US8080246B2 (en) | 2008-11-26 | 2011-12-20 | Five Prime Therapeutics, Inc. | Colony stimulating factor 1 receptor (CSF1R) extracellular domain fusion molecules |
ES2722300T3 (es) | 2009-12-10 | 2019-08-09 | Hoffmann La Roche | Anticuerpos que se unen preferentemente al dominio extracelular 4 de CSF1R y su uso |
CN102918060B (zh) | 2010-03-05 | 2016-04-06 | 霍夫曼-拉罗奇有限公司 | 抗人csf-1r抗体及其用途 |
US9221910B2 (en) | 2010-03-05 | 2015-12-29 | Hoffmann-La Roche Inc. | Antibodies against human CSF-1R |
SI2566517T1 (sl) | 2010-05-04 | 2019-01-31 | Five Prime Therapeutics, Inc. | Protitelesa, ki vežejo CSF1R |
US20110312506A1 (en) * | 2010-06-17 | 2011-12-22 | Dilyx Biotechnologies, LLC | Methods and kits for screening protein solubility |
WO2013087699A1 (en) | 2011-12-15 | 2013-06-20 | F. Hoffmann-La Roche Ag | Antibodies against human csf-1r and uses thereof |
US20130302322A1 (en) | 2012-05-11 | 2013-11-14 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
US20140079699A1 (en) | 2012-08-31 | 2014-03-20 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
WO2014093417A1 (en) | 2012-12-12 | 2014-06-19 | University Of Virginia Patent Foundation | Compositions and methods for regulating erythropoiesis |
AR095882A1 (es) | 2013-04-22 | 2015-11-18 | Hoffmann La Roche | Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9 |
AR097584A1 (es) | 2013-09-12 | 2016-03-23 | Hoffmann La Roche | Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano |
WO2015129263A1 (ja) | 2014-02-25 | 2015-09-03 | 株式会社クラレ | スフェロイド作製用デバイス、スフェロイドの回収方法及び製造方法 |
US11175268B2 (en) | 2014-06-09 | 2021-11-16 | Biometry Inc. | Mini point of care gas chromatographic test strip and method to measure analytes |
NZ727270A (en) | 2014-06-09 | 2022-07-29 | Biometry Inc | Low cost test strip and method to measure analyte |
WO2015200089A1 (en) | 2014-06-23 | 2015-12-30 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
US20160060597A1 (en) * | 2014-08-28 | 2016-03-03 | The University Of Maryland, Baltimore | Functional myelination of neurons |
TWI711463B (zh) | 2014-10-29 | 2020-12-01 | 美商戊瑞治療有限公司 | 用於癌症之組合療法 |
EP3215847A4 (en) * | 2014-11-03 | 2018-02-14 | Bioincept LLC | Pif binding as a marker for immune dysregulation |
BR112017013111A2 (pt) | 2014-12-22 | 2018-05-15 | Five Prime Therapeutics Inc | métodos de tratamento de um distúrbio e de tratamento da sinovite, uso de um anticorpo e anticorpo |
CN107709365A (zh) | 2015-04-13 | 2018-02-16 | 戊瑞治疗有限公司 | 癌症组合疗法 |
EP3487407A4 (en) | 2016-07-19 | 2019-11-13 | Biometry Inc. | METHOD AND SYSTEMS FOR MEASURING ANALYTES USING CALIBRATABLE TEST STRIPS |
EP3504239B1 (en) | 2016-08-25 | 2024-05-29 | F. Hoffmann-La Roche AG | Intermittent dosing of an anti-csf-1r antibody in combination with macrophage activating agent |
EP3558360A1 (en) | 2016-12-22 | 2019-10-30 | F. Hoffmann-La Roche AG | Treatment of tumors with an anti-csf-1r antibody in combination with an anti-pd-l1 antibody after failure of anti-pd-l1/pd1 treatment |
WO2018133937A1 (en) * | 2017-01-19 | 2018-07-26 | Biontech Ag | Engineered cells for inducing tolerance |
CN107130009A (zh) * | 2017-07-13 | 2017-09-05 | 华南理工大学 | 一种具有免疫活性和抗红细胞溶血活性的新型多肽及其制备方法 |
BR112020004879A2 (pt) | 2017-09-13 | 2020-09-15 | Five Prime Therapeutics, Inc. | métodos para tratar o câncer pancreático, para tratar o câncer e para determinar a responsividade de um sujeito com câncer |
CN109456989B (zh) * | 2018-10-31 | 2022-03-29 | 陕西慧康生物科技有限责任公司 | 一种提高毕赤酵母分泌表达的载体的构建方法 |
CN109593126B (zh) * | 2018-11-28 | 2019-11-22 | 山西锦波生物医药股份有限公司 | 多肽、其生产方法和用途 |
CN109468361B (zh) * | 2018-11-29 | 2021-11-02 | 电子科技大学 | 鱼类自然杀伤细胞杀伤细菌感染的单核/巨噬细胞能力的测定方法 |
CN109596839A (zh) * | 2018-12-25 | 2019-04-09 | 广州万孚生物技术股份有限公司 | 人和肽素快速定量检测方法与试剂盒 |
JP2022517029A (ja) * | 2019-01-15 | 2022-03-03 | アンセルム(アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル) | 変異したインターロイキン-34(il-34)ポリペプチドおよび治療におけるその使用 |
CN111150841B (zh) * | 2019-12-31 | 2023-08-15 | 优锐生物医药科技(深圳)有限公司 | 一种主动免疫调控微粒及其制备方法和应用 |
CN114113602A (zh) * | 2020-08-28 | 2022-03-01 | 香港城市大学深圳研究院 | 免疫球蛋白相关凝血因子x作为急性心肌梗死的生物标志物 |
WO2023014892A1 (en) * | 2021-08-04 | 2023-02-09 | Alpine Biotherapeutics Corporation | Sustainable ocular cell-mediated intraocular delivery of cellular therapeutics for treatment of ocular diseases or disorders |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
US4433092A (en) | 1981-03-09 | 1984-02-21 | Champion Spark Plug Company | Green ceramic of lead-free glass, conductive carbon, silicone resin and AlPO4, useful, after firing, as an electrical resistor |
US4873191A (en) | 1981-06-12 | 1989-10-10 | Ohio University | Genetic transformation of zygotes |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
US4736866B1 (en) | 1984-06-22 | 1988-04-12 | Transgenic non-human mammals | |
CA1255586A (en) | 1984-07-24 | 1989-06-13 | Hendrik M. Geysen | Method of determining mimotopes |
JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
US4631211A (en) | 1985-03-25 | 1986-12-23 | Scripps Clinic & Research Foundation | Means for sequential solid phase organic synthesis and methods using the same |
WO1987001130A1 (en) | 1985-08-15 | 1987-02-26 | Stauffer Chemical Company | Tryptophan producing microorganism |
JPS63501765A (ja) | 1985-11-01 | 1988-07-21 | インタ−ナショナル、ジェネティック、エンジニアリング インコ−ポレ−テッド | 抗体遺伝子のモジュ−ル組立体、それにより産生された抗体及び用途 |
US5831036A (en) * | 1987-05-04 | 1998-11-03 | Dana Farber Cancer Institute | Soluble fragments of human intercellular adhesion molecule-1 |
WO1989002468A1 (en) | 1987-09-11 | 1989-03-23 | Whitehead Institute For Biomedical Research | Transduced fibroblasts and uses therefor |
US6010902A (en) | 1988-04-04 | 2000-01-04 | Bristol-Meyers Squibb Company | Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity |
ATE135370T1 (de) | 1988-12-22 | 1996-03-15 | Kirin Amgen Inc | Chemisch modifizierte granulocytenkolonie erregender faktor |
EP0394827A1 (en) | 1989-04-26 | 1990-10-31 | F. Hoffmann-La Roche Ag | Chimaeric CD4-immunoglobulin polypeptides |
WO1991002067A1 (en) * | 1989-07-27 | 1991-02-21 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Regulation of nerve growth factor synthesis in the central nervous system |
US5464764A (en) | 1989-08-22 | 1995-11-07 | University Of Utah Research Foundation | Positive-negative selection methods and vectors |
US5350836A (en) * | 1989-10-12 | 1994-09-27 | Ohio University | Growth hormone antagonists |
US6552170B1 (en) | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
ES2120949T4 (es) | 1990-06-28 | 2011-12-29 | Sanofi-Aventis Deutschland Gmbh 50% | Proteinas de fusión con porciones de inmunoglobulinas, su preparación y empleo. |
US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
EP0575545B1 (en) | 1991-03-15 | 2003-05-21 | Amgen Inc. | Pegylation of polypeptides |
FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
US5399349A (en) | 1992-02-06 | 1995-03-21 | Paunescu; Calin | Treatment of acne |
US5480971A (en) | 1993-06-17 | 1996-01-02 | Houghten Pharmaceuticals, Inc. | Peralkylated oligopeptide mixtures |
CA2174132A1 (en) | 1993-10-14 | 1995-04-20 | Immunex Corporation | Fas antagonists and uses thereof |
US5643786A (en) * | 1995-01-27 | 1997-07-01 | The United States Of America As Represented By The Department Of Health And Human Services | Method for isolating dendritic cells |
US6395964B1 (en) | 1995-10-24 | 2002-05-28 | The Texas A&M University System | Oral immunization with transgenic plants |
BR9907950A (pt) | 1998-02-19 | 2001-12-18 | Xcyte Therapies Inc | Composições e processos para regulagem deativação de linfócitos |
US20040001826A1 (en) * | 1999-06-30 | 2004-01-01 | Millennium Pharmaceuticals, Inc. | Glycoprotein VI and uses thereof |
US20040048249A1 (en) * | 2000-01-21 | 2004-03-11 | Tang Y. Tom | Novel nucleic acids and secreted polypeptides |
US6436703B1 (en) * | 2000-03-31 | 2002-08-20 | Hyseq, Inc. | Nucleic acids and polypeptides |
AU2002232596A1 (en) * | 2000-12-13 | 2002-06-24 | Incyte Genomics, Inc. | Secreted human proteins |
WO2002068579A2 (en) * | 2001-01-10 | 2002-09-06 | Pe Corporation (Ny) | Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof |
CA2500521A1 (en) * | 2002-10-02 | 2004-09-23 | Nuvelo, Inc. | Novel nucleic acids and polypeptides |
-
2005
- 2005-07-21 EP EP12150386.6A patent/EP2479277B1/en not_active Not-in-force
- 2005-07-21 AT AT05791762T patent/ATE540973T1/de active
- 2005-07-21 EP EP05791762A patent/EP1778842B8/en not_active Not-in-force
- 2005-07-21 CA CA2574654A patent/CA2574654C/en not_active Expired - Fee Related
- 2005-07-21 US US11/632,319 patent/US20070264277A1/en not_active Abandoned
- 2005-07-21 JP JP2007522769A patent/JP5435865B2/ja not_active Expired - Fee Related
- 2005-07-21 AU AU2005267062A patent/AU2005267062C1/en not_active Ceased
- 2005-07-21 EP EP20100179665 patent/EP2287310B1/en not_active Not-in-force
- 2005-07-21 WO PCT/US2005/025941 patent/WO2006012451A2/en active Application Filing
-
2007
- 2007-05-29 HK HK07105690.5A patent/HK1100223A1/xx not_active IP Right Cessation
-
2009
- 2009-02-12 US US12/370,559 patent/US8178109B2/en active Active
-
2012
- 2012-04-13 US US13/446,254 patent/US8575312B2/en not_active Expired - Fee Related
- 2012-08-17 HK HK12108108.8A patent/HK1167432A1/zh not_active IP Right Cessation
-
2013
- 2013-10-08 US US14/048,834 patent/US20140170145A1/en not_active Abandoned
- 2013-10-31 JP JP2013226693A patent/JP5815638B2/ja not_active Expired - Fee Related
-
2015
- 2015-02-18 JP JP2015029580A patent/JP2015133970A/ja active Pending
-
2016
- 2016-05-24 JP JP2016103092A patent/JP2016146850A/ja active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2014034577A5 (ja) | ||
Jordan et al. | Human interferon lambda-1 (IFN-λ1/IL-29) modulates the Th1/Th2 response | |
Rochman et al. | The role of thymic stromal lymphopoietin in CD8+ T cell homeostasis | |
Hemeda et al. | Interferon-γ and tumor necrosis factor-α differentially affect cytokine expression and migration properties of mesenchymal stem cells | |
CN106659742B (zh) | 表达免疫应答刺激细胞因子以吸引和/或激活免疫细胞的基因修饰间充质干细胞 | |
da Silva Meirelles et al. | Mechanisms involved in the therapeutic properties of mesenchymal stem cells | |
Jones et al. | Loss of CD4+ T cell IL-6R expression during inflammation underlines a role for IL-6 trans signaling in the local maintenance of Th17 cells | |
Witte et al. | Despite IFN-λ receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: implications for therapeutic applications of these cytokines | |
Martini et al. | Aging induces cardiac mesenchymal stromal cell senescence and promotes endothelial cell fate of the CD90+ subset | |
Nakamura et al. | Bronchial epithelial cells regulate fibroblast proliferation | |
KR102650035B1 (ko) | 내열성 fgf2 폴리펩타이드 및 그 용도 | |
Liu et al. | Material viscoelastic properties modulate the mesenchymal stem cell secretome for applications in hematopoietic recovery | |
Zhao et al. | MAPK phosphatase-1 deficiency exacerbates the severity of imiquimod-induced psoriasiform skin disease | |
Malon et al. | Involvement of calcitonin gene-related peptide and CCL2 production in CD40-mediated behavioral hypersensitivity in a model of neuropathic pain | |
WO2021068068A1 (en) | Chimeric cytokine receptors | |
Shawki et al. | Immunomodulatory effects of umbilical cord‐derived mesenchymal stem cells | |
KR20150026839A (ko) | 면역조절능이 우수한 sRAGE 과발현 간엽줄기세포 및 이를 포함하는 면역질환의 예방 또는 치료용 세포치료제 조성물 | |
Ghahary et al. | Insulin‐like growth factor‐II/mannose 6 phosphate receptors facilitate the matrix effects of latent transforming growth factor‐β1 released from genetically modified keratinocytes in a fibroblast/keratinocyte co‐culture system | |
Kubota et al. | Inhibition of Interleukin-21 prolongs the survival through the promotion of wound healing after myocardial infarction | |
Ni et al. | The role of interferon regulatory factor 5 in macrophage inflammation during osteoarthritis | |
Hajam et al. | The expanding impact of T-regs in the skin | |
Chandrasekharan et al. | TNFR2 depletion reduces psoriatic inflammation in mice by downregulating specific dendritic cell populations in lymph nodes and inhibiting IL-23/IL-17 pathways | |
Lai et al. | A tetrameric form of CD40 ligand with potent biological activities in both mouse and human primary B cells | |
JP2024510671A (ja) | 腫瘍により誘導される再分極に対して抵抗性を有するヒトマクロファージ | |
Verma et al. | Stem cell therapy and innate lymphoid cells |